urovestВестник урологииUrology Herald2308-6424Rostov State Medical University10.21886/2308-6424-2024-12-3-79-87urovest-885Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESСравнительная оценка биодоступности компонентной смеси ботулотоксина А и тизоля с раствором ботулотоксина А для слизистой мочевого пузыря в экспериментеComparative evaluation of bioavailability of Botulinum toxin A complexed with Tizol (titanium glycerosolvate aquacomplex) versus pure Botulinum toxin A solution for bladder mucosa: an experimental studyhttps://orcid.org/0000-0001-6990-6482ПоройскийС. В.PoroyskiyS. V.

Сергей Викторович Поройский — д-р мед. наук, доцент

Волгоград

Sergey V. Poroyskiy — Dr.Sc.(Med), Assoc.Prof.(Docent)

Volgograd

poroyskiy@mail.ruhttps://orcid.org/0000-0002-4415-0903ПерлинД. В.PerlinD. V.

Дмитрий Владиславович Перлин — д-р мед. наук, профессор

Волгоград, Волжский, Волгоградская область

Dmitry V. Perlin — Dr.Sc.(Med), Full Prof.

Volgograd, Volzhsky, Volgograd region

dvperlin@mail.ruhttps://orcid.org/0000-0002-5681-0673СтруссовскаяО. Г.SrussovskayaO. G.

Ольга Геннадьевна Струссовская — д-р фарм. наук, доцент

Волгоград

Olga G. Strussovskaya — Dr.Sc.(Pharm) Assoc.Prof.(Docent)

Volgograd

strol3@yandex.ruhttps://orcid.org/0000-0002-2785-1986ГончаровН. А.GoncharovN. A.

Николай Александрович Гончаров

Волгоград

Nikolay А. Goncharov

Volgograd

goncharov1773@gmail.comhttps://orcid.org/0000-0002-7026-1746КузнецовА. А.KuznetsovA. A.

Александр Александрович Кузнецов — канд. мед. наук

Волгоград

Alexander A. Kuznetsov — Cand. Sc.(Med)

Volgograd

kouznetsov23@gmail.comhttps://orcid.org/0000-0001-9495-3424МорозовЕ. А.MorozovE. A.

Егор Андреевич Морозов

Волгоград

Egor A. Morozov

Volgograd

egor050795@rambler.ruВолгоградский государственный медицинский университетРоссияVolgograd State Medical UniversityRussian FederationВолгоградский государственный медицинский университет; Волгоградский областной уронефрологический центрРоссияVolgograd State Medical University; Volgograd Regional Urology and Nephrology CentreRussian FederationВолгоградский государственный медицинский университет; Волгоградская областная клиническая больница №1РоссияVolgograd State Medical University; Volgograd Regional Hospital No. 1Russian Federation2024080720241237987Copyright © Поройский С.В., Перлин Д.В., Струссовская О.Г., Гончаров Н.А., Кузнецов А.А., Морозов Е.А., 20242024Поройский С.В., Перлин Д.В., Струссовская О.Г., Гончаров Н.А., Кузнецов А.А., Морозов Е.А.Poroyskiy S.V., Perlin D.V., Srussovskaya O.G., Goncharov N.A., Kuznetsov A.A., Morozov E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.urovest.ru/jour/article/view/885Введение

Введение. Для лечения синдрома гиперактивного мочевого пузыря показано инъекционное введение ботулотоксина типа А (БоТ-А) в стенку мочевого пузыря. Разработка менее инвазивного способа введения БоТ-А позволила бы существенно расширить возможности коррекции синдрома гиперактивного мочевого пузыря.

Цель исследования

Цель исследования. Определить влияние тизоля на биологическую доступность БоТ-А для слизистой мочевого пузыря, сравнить её с биодоступностью БоТ-А.

Материалы и методы

Материалы и методы. В качестве экспериментальной модели для изучения изменения биодоступности БоТ-А в комплексе с тизолем и без в эксперименте in vitro, использовали модель диализа через слизистую оболочку мочевого пузыря телёнка. После проведённого диализа с помощью спектрофотометра определяли концентрацию БоТ-А в обоих образцах. В соответствии с полученными данными строили кривые диализа. Для определения биологической доступности БоТ-А использовали метод равновесного диализа по Крувчинскому. Для определения содержания БоТ-А в акцепторной среде применяли метод УФ-спектрофотометрии по реакции БоТ-А с реактивом Benedict.

Результаты

Результаты. Установлено, что максимальное количество БоТ-А диффундировало в акцепторную среду из смеси исследуемого вещества с тизолем через 9 часов. Площадь под кривой диализа смеси БоТ-А с тизолем превышает площадь под кривой БоТ-А почти на 20%, что свидетельствует об улучшении биологической доступности препарата в присутствии тизоля.

Заключение

Заключение. Компонентная смесь тизоля и БоТ-А обладает большей биодоступностью чем раствор чистого БоТ-А. Однако скорость диффузии компонентной смеси достаточна низка.

Introduction

Introduction. For the treatment of overactive bladder syndrome (OAB), injection of botulinum toxin A (BoNT-A) has been shown to be effective. However, there is a need for a less invasive method for administering BoNT-A, which could significantly expand the treatment options for OAB.

Objective

Objective. To assess the impact of tizol on the absorption of BoNT-A by the bladder mucosa and compare it to the individual absorption of BoNT-A.

Materials & Methods

Materials & Methods. Dialysis through the mucous membrane of the сalf bladder was used as an experimental model to study changes in bioavailability of BoNT-A complexed with tisol (BoNT-A + T) and pure BoNT-A solution during in vitro experiment. After dialysis, the BoNT-A concentration in both samples was determined using a spectrophotometer. Dialysis curves were plotted according to the data obtained. Kruvchinsky equilibrium dialysis method was used to determine botulinum toxin A bioavailability. The UV spectrophotometry method was used to determine the concentration of BoNT-A in the acceptor medium by reaction of BoNT-A with Benedict's reagent.

Results

Results. It was established that the maximum concentration of BoNT-A diffused into the acceptor medium from the blend of the test substance with tizol after nine hours. The area under the curve for dialysis of BoNT-A + T exceeds the area under the curve of pure BoNT-A by almost 20%, suggesting an improvement in the drug's bioavailability when blended with tizol.

Conclusion

Conclusion. Based on our experiment, it was found out that the BoNT-A + T has greater bioavailability than a solution of pure BoNT-A. However, the diffusion rate of the component mixture is sufficiently low.

ботулотоксин Атизольглицеросольват титанауротелийгиперактивный мочевой пузырьbotulinum toxin Atizoltitanium glycerosolvateurotheliumhyperactive bladderReferencesLewis SA. Everything you wanted to know about the bladder epithelium but were afraid to ask. Am J Physiol Renal Physiol. 2000;278(6):F867-F874. DOI: 10.1152/ajprenal.2000.278.6.F867Lewis SA. Everything you wanted to know about the bladder epithelium but were afraid to ask. Am J Physiol Renal Physiol. 2000;278(6):F867-F874. DOI: 10.1152/ajprenal.2000.278.6.F867Jafari NV, Rohn JL. The urothelium: a multi-faceted barrier against a harsh environment. Mucosal Immunol. 2022;15(6):1127-1142. DOI: 10.1038/s41385-022-00565-0Jafari NV, Rohn JL. The urothelium: a multi-faceted barrier against a harsh environment. Mucosal Immunol. 2022;15(6):1127-1142. DOI: 10.1038/s41385-022-00565-0Dalghi MG, Montalbetti N, Carattino MD, Apodaca G. The Urothelium: Life in a Liquid Environment. Physiol Rev. 2020;100(4):1621-1705. DOI: 10.1152/physrev.00041.2019Dalghi MG, Montalbetti N, Carattino MD, Apodaca G. The Urothelium: Life in a Liquid Environment. Physiol Rev. 2020;100(4):1621-1705. DOI: 10.1152/physrev.00041.2019Kachar B, Liang F, Lins U, Ding M, Wu XR, Stoffler D, Aebi U, Sun TT. Three-dimensional analysis of the 16 nm urothelial plaque particle: luminal surface exposure, preferential head-to-head interaction, and hinge formation. J Mol Biol. 1999;285(2):595-608. DOI: 10.1006/jmbi.1998.2304Kachar B, Liang F, Lins U, Ding M, Wu XR, Stoffler D, Aebi U, Sun TT. Three-dimensional analysis of the 16 nm urothelial plaque particle: luminal surface exposure, preferential head-to-head interaction, and hinge formation. J Mol Biol. 1999;285(2):595-608. DOI: 10.1006/jmbi.1998.2304Klingler CH. Glycosaminoglycans: how much do we know about their role in the bladder? Urologia. 2016;83 Suppl 1:11-14. DOI: 10.5301/uro.5000184Klingler CH. Glycosaminoglycans: how much do we know about their role in the bladder? Urologia. 2016;83 Suppl 1:11-14. DOI: 10.5301/uro.5000184Shashikanth N, Yeruva S, Ong MLDM, Odenwald MA, Pavlyuk R, Turner JR. Epithelial Organization: The Gut and Beyond. Compr Physiol. 2017;7(4):1497-1518. DOI: 10.1002/cphy.c170003Shashikanth N, Yeruva S, Ong MLDM, Odenwald MA, Pavlyuk R, Turner JR. Epithelial Organization: The Gut and Beyond. Compr Physiol. 2017;7(4):1497-1518. DOI: 10.1002/cphy.c170003Abir-Awan M, Kitchen P, Salman MM, Conner MT, Conner AC, Bill RM. Inhibitors of Mammalian Aquaporin Water Channels. Int J Mol Sci. 2019;20(7):1589. DOI: 10.3390/ijms20071589Abir-Awan M, Kitchen P, Salman MM, Conner MT, Conner AC, Bill RM. Inhibitors of Mammalian Aquaporin Water Channels. Int J Mol Sci. 2019;20(7):1589. DOI: 10.3390/ijms20071589Birder LA. More than just a barrier: urothelium as a drug target for urinary bladder pain. Am J Physiol Renal Physiol. 2005;289(3):F489-F495. DOI: 10.1152/ajprenal.00467.2004Birder LA. More than just a barrier: urothelium as a drug target for urinary bladder pain. Am J Physiol Renal Physiol. 2005;289(3):F489-F495. DOI: 10.1152/ajprenal.00467.2004Birder L, Andersson KE. Urothelial signaling. Physiol Rev. 2013;93(2):653-680. DOI: 10.1152/physrev.00030.2012Birder L, Andersson KE. Urothelial signaling. Physiol Rev. 2013;93(2):653-680. DOI: 10.1152/physrev.00030.2012Gonzalez EJ, Merrill L, Vizzard MA. Bladder sensory physiology: neuroactive compounds and receptors, sensory transducers, and target-derived growth factors as targets to improve function. Am J Physiol Regul Integr Comp Physiol. 2014;306(12):R869-R878. DOI: 10.1152/ajpregu.00030.2014Gonzalez EJ, Merrill L, Vizzard MA. Bladder sensory physiology: neuroactive compounds and receptors, sensory transducers, and target-derived growth factors as targets to improve function. Am J Physiol Regul Integr Comp Physiol. 2014;306(12):R869-R878. DOI: 10.1152/ajpregu.00030.2014Burnstock G. Purinergic signalling in the lower urinary tract. Acta Physiol (Oxf). 2013;207(1):40-52. DOI: 10.1111/apha.12012Burnstock G. Purinergic signalling in the lower urinary tract. Acta Physiol (Oxf). 2013;207(1):40-52. DOI: 10.1111/apha.12012Li Y, Xue L, Miao Q, Mao F, Yao L, Yuan J, Qin W, Zhao Y, Sun H, Liu F, Wang H. Expression and electrophysiological characteristics of P2X3 receptors in interstitial cells of Cajal in rats with partial bladder outlet obstruction. BJU Int. 2013;111(5):843-851. DOI: 10.1111/j.1464-410X.2012.11408.xLi Y, Xue L, Miao Q, Mao F, Yao L, Yuan J, Qin W, Zhao Y, Sun H, Liu F, Wang H. Expression and electrophysiological characteristics of P2X3 receptors in interstitial cells of Cajal in rats with partial bladder outlet obstruction. BJU Int. 2013;111(5):843-851. DOI: 10.1111/j.1464-410X.2012.11408.xDeruyver Y, Voets T, De Ridder D, Everaerts W. Transient receptor potential channel modulators as pharmacological treatments for lower urinary tract symptoms (LUTS): myth or reality? BJU Int. 2015;115(5):686-697. DOI: 10.1111/bju.12876Deruyver Y, Voets T, De Ridder D, Everaerts W. Transient receptor potential channel modulators as pharmacological treatments for lower urinary tract symptoms (LUTS): myth or reality? BJU Int. 2015;115(5):686-697. DOI: 10.1111/bju.12876Skryma R, Prevarskaya N, Gkika D, Shuba Y. From urgency to frequency: facts and controversies of TRPs in the lower urinary tract. Nat Rev Urol. 2011;8(11):617-630. DOI: 10.1038/nrurol.2011.142Skryma R, Prevarskaya N, Gkika D, Shuba Y. From urgency to frequency: facts and controversies of TRPs in the lower urinary tract. Nat Rev Urol. 2011;8(11):617-630. DOI: 10.1038/nrurol.2011.142Andersson KE, Gratzke C, Hedlund P. The role of the transient receptor potential (TRP) superfamily of cation-selective channels in the management of the overactive bladder. BJU Int. 2010;106(8):1114-1127. DOI: 10.1111/j.1464-410X.2010.09650.xAndersson KE, Gratzke C, Hedlund P. The role of the transient receptor potential (TRP) superfamily of cation-selective channels in the management of the overactive bladder. BJU Int. 2010;106(8):1114-1127. DOI: 10.1111/j.1464-410X.2010.09650.xBø K, Hilde G. Does it work in the long term?--A systematic review on pelvic floor muscle training for female stress urinary incontinence. Neurourol Urodyn. 2013;32(3):215-223. DOI: 10.1002/nau.22292Bø K, Hilde G. Does it work in the long term?--A systematic review on pelvic floor muscle training for female stress urinary incontinence. Neurourol Urodyn. 2013;32(3):215-223. DOI: 10.1002/nau.22292Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential cation channels in disease. Physiol Rev. 2007;87(1):165-217. DOI: 10.1152/physrev.00021.2006Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential cation channels in disease. Physiol Rev. 2007;87(1):165-217. DOI: 10.1152/physrev.00021.2006Szallasi A. Vanilloid receptor ligands: hopes and realities for the future. Drugs Aging. 2001;18(8):561-573. DOI: 10.2165/00002512-200118080-00001Szallasi A. Vanilloid receptor ligands: hopes and realities for the future. Drugs Aging. 2001;18(8):561-573. DOI: 10.2165/00002512-200118080-00001Kim JH, Rivas DA, Shenot PJ, Green B, Kennelly M, Erickson JR, O'Leary M, Yoshimura N, Chancellor MB. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med. 2003;26(4):358-363. DOI: 10.1080/10790268.2003.11753706Kim JH, Rivas DA, Shenot PJ, Green B, Kennelly M, Erickson JR, O'Leary M, Yoshimura N, Chancellor MB. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med. 2003;26(4):358-363. DOI: 10.1080/10790268.2003.11753706Szallasi A, Fowler CJ. After a decade of intravesical vanilloid therapy: still more questions than answers. Lancet Neurol. 2002;1(3):167-172. DOI: 10.1016/s1474-4422(02)00072-8Szallasi A, Fowler CJ. After a decade of intravesical vanilloid therapy: still more questions than answers. Lancet Neurol. 2002;1(3):167-172. DOI: 10.1016/s1474-4422(02)00072-8Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. Intracellular bacterial biofilm-like pods in urinary tract infections. Science. 2003;301(5629):105-107. DOI: 10.1126/science.1084550Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. Intracellular bacterial biofilm-like pods in urinary tract infections. Science. 2003;301(5629):105-107. DOI: 10.1126/science.1084550Hicks RM. The mammalian urinary bladder: an accommodating organ. Biol Rev Camb Philos Soc. 1975;50(2):215-246. DOI: 10.1111/j.1469-185x.1975.tb01057.xHicks RM. The mammalian urinary bladder: an accommodating organ. Biol Rev Camb Philos Soc. 1975;50(2):215-246. DOI: 10.1111/j.1469-185x.1975.tb01057.xBerzin S.A., Zamyatin A.V., Mager V.O. Tizol distribution in the bladder wall in patients with invasive bladder cancer. Siberian journal of oncology. 2009;(S2):26-27. (In Russian).eLIBRARY ID: 12918927; EDN: KWSIKBBerzin S.A., Zamyatin A.V., Mager V.O. Tizol distribution in the bladder wall in patients with invasive bladder cancer. Siberian journal of oncology. 2009;(S2):26-27. (In Russian).eLIBRARY ID: 12918927; EDN: KWSIKBНедержание мочи. Клинические рекомендации. М.; 2021.Urinary incontinence. Russian clinical guidelines. Moscow; 2021. (In Russian).Guidelines EAU 2022. EAU Guidelines Office, Arnhem, The Netherlands; 2023.Guidelines EAU 2022. EAU Guidelines Office, Arnhem, The Netherlands; 2023.Kalder M, Pantazis K, Dinas K, Albert US, Heilmaier C, Kostev K. Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence. Obstet Gynecol. 2014;124(4):794-800. DOI: 10.1097/AOG.0000000000000468Kalder M, Pantazis K, Dinas K, Albert US, Heilmaier C, Kostev K. Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence. Obstet Gynecol. 2014;124(4):794-800. DOI: 10.1097/AOG.0000000000000468Jiang YH, Liao CH, Kuo HC. Current and potential urological applications of botulinum toxin A. Nat Rev Urol. 2015;12(9):519-533. DOI: 10.1038/nrurol.2015.193Jiang YH, Liao CH, Kuo HC. Current and potential urological applications of botulinum toxin A. Nat Rev Urol. 2015;12(9):519-533. DOI: 10.1038/nrurol.2015.193Kuo HC, Liu HT, Chuang YC, Birder LA, Chancellor MB. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur Urol. 2014;65(6):1117-1124. DOI: 10.1016/j.eururo.2014.01.036Kuo HC, Liu HT, Chuang YC, Birder LA, Chancellor MB. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur Urol. 2014;65(6):1117-1124. DOI: 10.1016/j.eururo.2014.01.036Hung FC, Kuo HC. Liposome-Encapsulated Botulinum Toxin A in Treatment of Functional Bladder Disorders. Toxins (Basel). 2022;14(12):838. DOI: 10.3390/toxins14120838Hung FC, Kuo HC. Liposome-Encapsulated Botulinum Toxin A in Treatment of Functional Bladder Disorders. Toxins (Basel). 2022;14(12):838. DOI: 10.3390/toxins14120838

The authors declare that there are no conflicts of interest present.